John Fanikos Praises Nathan Connell’s Efforts on Hemophilia Gene Therapy in Boston
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared a post on LinkedIn:
“Hemophilia historically has been seen as a ‘royal disease’ because of its occurrence in the royal families of Spain, Germany and Russia.
Today it is known as a genetic disorder where bleeding occurs because of low levels of blood clotting Factor 8 (VIII) or Factor 9 (IX). As simple as a missing gene on a chromosome that provides the blueprint for the protein Factor.
Enter gene therapy.
Kudos to Dr Nathan Connell, who worked feverishly to bring this treatment to the Boston area.
You can hear the treatment results of his first patient on the CBS news and follow his expertise at the Vasculearn Network”
Nathan Connell’s first patient results featured on CBS News.
Follow his expertise on the Vasculearn Network.
Stay informed with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning